Literature DB >> 10203493

Use of a novel hepatitis C virus (HCV) major-epitope chimeric polypeptide for diagnosis of HCV infection.

D Y Chien1, P Arcangel, A Medina-Selby, D Coit, M Baumeister, S Nguyen, C George-Nascimento, A Gyenes, G Kuo, P Valenzuela.   

Abstract

The genome of hepatitis C virus (HCV) consists of seven functional regions: the core, E1, E2/NS1, NS2, NS3, NS4, and NS5 regions. The U. S. Food and Drug Administration-licensed 2.0G immunoassay for the detection of anti-HCV uses proteins from the core, NS3, and NS4 regions (McHutchinson et al., Hepatology 15:19-25, 1992). The 3.0G enzyme-linked immunosorbent assay includes the protein from the NS5 region (Uyttendaele et al., Vox Sang. 66:122-129, 1994). The necessity of detecting antibodies to viral envelope proteins (E1 and E2) and to different genotype samples has been demonstrated previously (Chien et al., Lancet 342:933, 1993; Lok et al., Hepatology 18:497-502, 1993). In this study we have attempted to improve the sensitivity of the anti-HCV assay by developing a single multiple-epitope fusion antigen (MEFA; MEFA-6) which incorporates all of the major immunodominant epitopes from the seven functional regions of the HCV genome. A nucleic acid sequence consisting of proteins from the viral core, E1, E2, NS3, NS4, and NS5 regions and different subtype-specific regions of the NS4 region was constructed, cloned, and expressed in yeast. The epitopes present on this antigen can be detected by epitope-specific monoclonal and polyclonal antibodies. In a competition assay, the MEFA-6 protein competed with 83 to 96% of genotype-specific antibodies from HCV genotype-specific peptides. This recombinant antigen was subsequently used to design an anti-HCV chemiluminescent immunoassay. We designed our assay using a monoclonal anti-human immunoglobulin G antibody bound to the solid phase. Because MEFA-6 is fused with human superoxide dismutase (h-SOD), we used an anti-human superoxide dismutase, dimethyl acridinium ester-labeled monoclonal antibody for detection. Our results indicate that MEFA-6 exposes all of the major immunogenic epitopes. Its excellent sensitivity and specificity for the detection of clinical seroconversion are demonstrated by this assay.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203493      PMCID: PMC84783     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Improved detection of hepatitis C virus antibodies in high-risk populations.

Authors:  J G McHutchison; J L Person; S Govindarajan; B Valinluck; T Gore; S R Lee; M Nelles; A Polito; D Chien; R DiNello
Journal:  Hepatology       Date:  1992-01       Impact factor: 17.425

2.  Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients.

Authors:  A S Lok; D Chien; Q L Choo; T M Chan; E K Chiu; I K Cheng; M Houghton; G Kuo
Journal:  Hepatology       Date:  1993-09       Impact factor: 17.425

3.  Persistence of HCV despite antibodies to both putative envelope glycoproteins.

Authors:  D Y Chien; Q L Choo; R Ralston; R Spaete; M Tong; M Houghton; G Kuo
Journal:  Lancet       Date:  1993-10-09       Impact factor: 79.321

4.  A second group of hepatitis C viruses.

Authors:  K Tsukiyama-Kohara; M Kohara; K Yamaguchi; N Maki; A Toyoshima; K Miki; S Tanaka; N Hattori; A Nomoto
Journal:  Virus Genes       Date:  1991-07       Impact factor: 2.332

5.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

6.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

7.  Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus.

Authors:  W M Ching; C Wychowski; M J Beach; H Wang; C L Davies; M Carl; D W Bradley; H J Alter; S M Feinstone; J W Shih
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

8.  Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease.

Authors:  D Y Chien; Q L Choo; A Tabrizi; C Kuo; J McFarland; K Berger; C Lee; J R Shuster; T Nguyen; D L Moyer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

10.  Evaluation of third-generation screening and confirmatory assays for HCV antibodies.

Authors:  S Uyttendaele; H Claeys; W Mertens; H Verhaert; C Vermylen
Journal:  Vox Sang       Date:  1994       Impact factor: 2.144

View more
  3 in total

1.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Design of novel conformational and genotype-specific antigens for improving sensitivity of immunoassays for hepatitis C virus-specific antibodies.

Authors:  Sansan Lin; Phillip Arcangel; Angelica Medina-Selby; Doris Coit; Philip Ng; Steve Nguyen; Colin McCoin; Alex Gyenes; Celine Hu; Laura Tandeske; Bruce Phelps; David Chien
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  High levels of subgenomic HCV plasma RNA in immunosilent infections.

Authors:  Flavien Bernardin; Susan L Stramer; Barbara Rehermann; Kimberly Page-Shafer; Stewart Cooper; David R Bangsberg; Judith Hahn; Leslie Tobler; Michael Busch; Eric Delwart
Journal:  Virology       Date:  2007-05-09       Impact factor: 3.616

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.